proteome metadata and coordinates data were downloaded from the SWISSMODEL Repository (UniprotKB release 2018_05) and were included if the QMEAN Z-score >-4. We defined secondary structure in the models with DSSP-2.0.4 ((4); ftp://ftp.cmbi.ru.nl/pub/software/dssp/) and we defined 3D sites using the secondary structure elements. The fraction of the canonical Uniprot sequence length covered by structure for proteins from both the PDB and SWISSMODEL is shown in Fig. S5 . Quantification of Depletion of Variation and Creation of a 3D-Tolerance Score (3DTS). We model the probability of observing a missense mutation at a coding locus l as pl * sl * bl. pl is the expected number of mutations between the reference genome and the sample assuming that mutations at the locus are neutral, bl is how likely a nucleotide change leads to a missense variation and sl is an adjustment factor. We learn pl on neutral variants (see below) and infer our parameter of interest is sl which in its two extremes is either 0 if all variation happening at the locus is deleterious or 1 if none is. At a given locus, all parameters are the same across samples, thus aggregating R samples yields a binomial distribution as the number of samples with a missense mutation at locus l. Using the Poisson approximation, the probability of observing at least one missense mutation in R samples in a single locus is 1 -exp(-pl * sl * bl* Rl). For a given locus, the number of called positions across a population can vary therefore necessitating the index l on the parameter R. Each locus has different bl and Rl parameters thus aggregating K>1 loci into a single unit is a sum of Bernoulli trials of heterogeneous parameters. This we approximate again with a Poisson distribution following Le Cam's theorem. The final likelihood function of our model is
-exp(-pl s bl Rl)) .
The above model has two nuisance parameters bl and pl. We know bl from the genetic code and reading frame. We learn pl by two approaches seeking to maintain the assumption that variants used for training are neutral: 1) from the chromosome-specific non-coding variation data (described in the text and methods as the "constant mutation rate") 2) from the nucleotide context dependent chromosome-specific non-coding variation data (described in the text and methods as the "heptamer rate"). To these data we apply the previously described model and find the value or values of pl which maximizes the likelihood. To do so we set s to 1 assuming that mutations in these regions do not confer deleteriousness, and encode our constraint that we would like s to quantify the difference between the coding region of interest and the neutral territories. We introduce a function h from the set of genetic loci to the set of 16,384 7-mers where h(l) is the 7-mer which symmetrically spans the locus in the reference genome. We calculate nucleotide context dependent estimates of pl by partitioning all intergenic loci by h. We compute the corresponding maximum likelihood estimate of the expected number of mutations (p) for each of the 16,384 possible partitions using the above formula by setting s to 1 as before, and letting l iterate over all intergenic loci of a partition. We use these estimates of p in the coding region according to the above formula except that p is indexed by the heptamer of a locus (h(l)) instead of the locus (l). It should be noted that 98.5% of 3D sites do not contain a common missense variant (AF>0.05) and would not be affected by the incorporation of an allele frequency term -this is the rationale to favoring a model that uses context (k-mer) expectation of variation (Fig. S6) . We take advantage that the problem is one dimensional and use numerical integration (Gauss-Legendre quadrature and importance sampling) to calculate the posterior mean on s with a uniform U(0,1) prior. We provide downstream analysis of the posterior mean of s as the 3D tolerance score (3DTS) elsewhere in the paper. Analyses described in the main text use the constant mutation rate, except when comparing the effects of varying these parameters, as in Figure 2B , and when describing the optimal 3DTS model in Figure 2C . The "Structure" feature set, which uses secondary structure elements only, was used in the cases of Figure 2A and 2D. In the case of Figures 1 and 3 , all features were used. The optimal model was defined by the highest Pearson r 2 value that showed correct directionality in correlation and that had both significant Pearson and Spearman p-values (p<0.05) (Additional Data Table S1 ). In the case of TPMT, which did not meet the Pearson p-value threshold of significance, the model showing a significant Spearman p-value was considered optimal. Functional Data and Pathogenicity Scores. Deep mutational scanning data are available for PPARG (5), MAPK1/ERK2 (6), p53 (7), PTEN and TPMT (8), UBE2I , SUMO1, TPK1, CALM1, CALM2 and CALM3 (9), and two single protein domains of BRCA1 (the RING domain) and YAP65 (the WW domain) ) (10, 11) . Functional in vitro data for PPARG were sourced from Majithia et. al. (5) The integrated functional scores available through http://miter.broadinstitute.org/ (Data version 1.0) were used. Only those scores linked to amino acid changes resulting from a single nucleotide variation (SNV) were used in the comparison with 3DTS. MAPK1/ERK2 data was sourced from Supplementary Table S1 in reference (6) . The log-fold2 change of ERK2 mutant abundance following DOX induction relative to the mutant abundance in the early time point for missense variants caused by SNVs were averaged for an amino acid site and then averaged across a 3D site for the comparison with 3DTS. PTEN and TPMT data were sourced from Supplementary Datasets 3 and 4 in reference (8) . The "score" columns were averaged across each 3D site and compared to 3DTS. UBE2I, SUMO1, TPK1, CALM1, and CALM2 data were sourced from Dataset EV1 in reference (9) . The "joint.score" column was averaged across an amino acid position for missense variants and then averaged across a 3D site and compared to 3DTS. We did not score p53 because we could not retrieve quantitative information at the residue/feature level from the original publication; we did not score CALM3 because no structure is available for this. We do not include the analysis of limited data for the RING domain of BRCA1 or the WW domain in YAP65. Comparative method data were sourced from dbNSFPv3.5a (12, 13) except for EVmutation (14) data, which were sourced from (https://marks.hms.harvard.edu/evmutation/human_proteins.html). The data fields used were: "CADD_phred" (CADD), "MutationAssessor_score" (MutationAssessor), "fathmm-MKL_coding_score" (FATHMM-MKL), "integrated_fitCons_score" (fitCons), "DANN_score" (DANN), "MetaSVM_score" (MetaSVM), "MetaLR_score" (MetaLR), "GenoCanyon_score" (GenoCanyon), "Eigen-PC-phred" (Eigen), "M-CAP_score" (M-CAP), "REVEL_score" (REVEL), "phyloP100way_vertebrate" (phyloP_vertebrate), "phyloP20way_mammalian" (phyloP_mammalian), "phastCons100way_vertebrate" (phastCons_vertebrate), "phastCons20way_mammalian" (phastCons_mammalian), "GERP++_RS" (GERP), "SiPhy_29way_logOdds" (SiPhy), "Polyphen2_HDIV_score" (Polyphen2_HDIV), "Polyphen2_HVAR_score" (Polyphen2_HVAR) and "prediction_epistatic" (EVmutation). Scores resulting in missense variants were averaged across a nucleotide (where applicable), then an amino acid position and lastly across a 3D site. 3D sites were defined by the features showing the lowest 3DTS value for an amino acid position and correlations were made over available data. Drug Ligand Data Set and Analyses. A set of structures defined as therapeutic targets of FDA-approved drugs was used. Therapeutic targets were taken from the supplementary information of Santos et al. (15) Of 667 non-redundant Uniprot entries, 361 contained some structural information and 100 contained proteins where the sequence length of the structure defined by Uniprot covered at least 80% of the canonical Uniprot sequence. Ninety-four of these 100 proteins were mapped to the genome using Gencode version 26lift37. These 94 proteins were examined for the presence of the corresponding bound therapeutic molecule or analog in a structure; when not found, homologous structures containing these molecules were superimposed, resulting in 48 structures with their corresponding "bound" therapeutic molecule (for a list of these structures and their "bound" ligands, see Additional data table S3). Ligand binding sites were defined as those residues within 5 Å of any of the bound therapeutic molecule residues. Anatomical Therapeutic Chemical (ATC) Classification System Data and Analyses. Drug-liganded molecules (as identified in the above Drug Ligand Data Set and Analyses section) were assigned to their ATC codes using the supplementary information of Santos et al. (15) For each structure, a non-redundant list of top-level ATC code was included for all bound drugs. In cases in which no ATC code was found, the code was inferred either based on indication (when available) or based on indirect effect. In cases where the structure had multiple chains contributing to the ligand-binding site, the median score was used in defining tolerance. Allosteric Data Set and Analyses. The XML data of the Allosteric Database (Release 3.06)(16) was downloaded and parsed with custom Python scripts. Data was used if the field "Organism_Latin" was equal to "Homo sapiens", any of the allosteric counts ("Allosteric_Activator_Count", "Allosteric_Inhibitor_Count", or "Allosteric_Regulator_Count") had a value of at least one, and "Site_Detail" contained at least one defined amino acid. Of the resultant fifty-four entries, fifty structures were mapped where every allosteric residue had a 3DTS value. These structures were used in the downstream analysis (for a list of these structures, see Additional data table S3). Active Site Data Set and Analyses. A non-redundant list of protein active sites was included for those structures found in the Drug Ligand Data Set and the Allosteric Data Set. Active sites were defined based on the 5 Å context of the "ACT_SITE" feature(s) defined in Uniprot (i.e., "ACT_SITE" 3D-sites). Protein-Protein Interactions Data Set and Analyses. Protein-protein interface contacts were extracted from PDBsum (http://www.ebi.ac.uk/pdbsum; (17)) from each PDB entry's protein-protein interface page (where available) for PDBs within the Drug Ligand Data Set, Active Site Data Set and Allosteric Data Set. Unique, Non-Overlapping 3D-Intolerant Site Analyses. Structures from the Drug Ligand Data Set and Allosteric Data Set were used. A 3D-site was defined as intolerant if
